The United States of America, As Represented by the Secretary, Department of Health and Human Services

University of Iowa Research Foundation

Universitat Rovira I Virgili

The United States of America As Represented by the Department of Health

Brigham Young University

University of Delaware

University of Hawai'i

The United States of America

University of Leeds

Fundacio Institut Catala D'investigacio Quimica (iciq)

Fundacio Institut Catala D'investigacio Quimica

The United States of America, National Institute of Health

John M. Roach

Jerzy Golik

John A. Beutler

John A Beutler

David Wiemer

Michael R Boyd

Leonard M Neckers

John H Cardellina, Ii

W Marston Linehan

Jane B Neckers

Jeffrey D Neighbors

Antonio Echavarren

Fernando Bravo

William J Chain

Min-Jung Lee

Bradley T Scroggins

James Brislin McMahon

Craig J Thomas

Peter M Blumberg

Paul Alan Cox

William Douglas Figg

Zhenwu Li

Gordon M Cragg

Jian-kang Jiang

Lewis K Pannell

David Covell

Sunmin Lee

Ranjala Ratnayake

Tawnya C McKee

Joe William Ramos

David John Beech

Karen L Erickson

Carole Ac Sourbier

Tanya Tannaquil Ransom

Stuart F J LeGrice

Suhman Chung

Jennifer Wilson

Karlyne Reilly

Thomas Turbyville

Hussein Rubaiy

Tanya R Johnson

David Fash

Deborah Galinis

Cody John Peer

Junichi Ishitoya

Nancy A Sharkey

Krik R Gustafson

Florian J Sulzmaier

Owen S Weislow

Carole Sourbier

Zhenhua Wu

Laura Lopez

Jean-Simon Suppo

Lorena Riesgo

David F Wiemer

William D Figg

Antonio M Echavarren

Patrick K Clark

John M Roach

Gary M Muschik

Iii Lebherz William B

John T Ross

William Chain

Disclosed is a compound of formula (I) in which a, R-Rand Xare as described herein. Also disclosed are a pharmaceutical composition containing the compound and a method of using the compound for treating cancer, such as renal cancer.

Englerin derivatives for treatment of cancer

Disclosed is a compound of formula (I) in which R-Rand Xare as described herein. Also provided are methods of using a compound of formula (I), including a method of treating cancer and a method of treating diabetes. 

Epoxyazulene derivatives useful for treating cancer and diabetes

Disclosed is a compound of formula (I) or formula (II): (Formulas should be inserted here) wherein R-Rare as defined herein. Also disclosed are a pharmaceutical composition comprising such a compound and a method of treating or preventing cancer in a mammal in need thereof, comprising administering to the mammal a compound of formula (I) or formula (II). 

Aza-epoxy-guaiane derivatives and treatment of cancer

Disclosed is a method of activating protein kinase C theta (PKC&#x3b8;) in an HIV or HTLV infected animal comprising administering to the animal an effective amount of a compound of formula (I): Formula (I), or an epimer thereof; wherein Ar and R-Rare described herein. Examples of diseases or conditions associated with PKC&#x3b8; include HIV1 infection, AIDS, HTLV infection, and adult T cell leukemia/lymphoma. 

Methods of treating patients infected with HIV and HTLV

Disclosed are methods of treating an animal for insulin resistance and associated diseases or conditions, activating the transcriptional activity of heat shock factor 1 (HSF1), or inducing the expression of heat shock protein 70 (HSP70) in an animal in need thereof, wherein the methods involve administering an effective amount of one or more compounds of formula (I) or an epimer thereof, wherein Ar, and R-Rare described herein. Examples of diseases or conditions associated with insulin resistance include diabetes, obesity, inflammation, metabolic syndrome, polycystic ovary disease, arteriosclerosis, non-alcoholic fatty liver disease, reproductive abnormality in a female, and growth abnormality. 

Methods of treating or preventing insulin resistance and associated diseases and conditions

Disclosed are compounds that inhibit RNase H activity of retroviruses, for example, a compound of formula (I) wherein R, R, and Rare as described herein, as well as pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof. Pharmaceutical compositions comprising such compounds, as well as methods of use, and treatment or prevention of infection by human immunodeficiency virus (HIV). 

Tropolone compounds for treating or preventing retroviral infection

Disclosed is a method for preventing or treating an undesirable condition in a subject carrying cells homozygous null for the neurofibromatosis type 1 gene or subjects that are haploinsufficient for the neurofibromatosis type 1 gene, the method comprising administering to a subject in need thereof an effective amount of a schweinfurthin or schweinfurthin analog or derivative, or a pharmaceutically acceptable salt, prodrug, hydrate, or solvate thereof. Also disclosed is a new schweinfurthin compound of the formula. 

Schweinfurthins and uses thereof

Disclosed are englerins and derivatives (I) thereof useful in the treatment of a number of cancers, particularly renal cancer, as well as pharmaceutical compositions and method of treating a patient with the use of these derivatives. The englerins, for example Englerin A and Englerin B, can be isolated from the plantor produced by synthetic methods. An example of the englerin derivative is 2'-chloroenglerin A, which has the structure (II), wherein double bond 'a' is E, Z, or a mixture of E and Z. 

Epoxy-guaiane derivatives and treatment of cancer

Methods and intermediates for preparing enantiomerically enriched Schweinfurthin analogs which are useful for the treatment of cancer, as well as novel Schweinfurthin analogs having anti-cancer activity, compositions comprising such analogs and therapeutic methods comprising administering such analogs.

Schweinfurthin analogues

Macrocyclic lactones, compositions, and methods of use

The present invention relates to an antiviral composition and to methods of treating patients with viral infections. The antiviral composition of the present invention comprises prostratin, a phorbol ester derivative, and a pharmaceutically acceptable carrier. The present composition while having antiviral activity does not have substantial tumor promoting activity and does not have other substantial adverse toxicological properties that would preclude its use in antiviral therapy.

Antiviral composition

Growing community of inventors

Union Bridge, MD, United States of America

John A Beutler